The transcription factor Nrf2 exerts beneficial effects against cardiovascular injury (for example, doxorubicin (DOX)-induced cardiotoxicity, diabetic cardiomyopathy (DCM) and cardiorenal syndrome (CRS)) by maintaining the redox equilibrium. This evidence concerns the gene NFE2L2 and diabetic cardiomyopathy.